|
May 15
|
BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering
|
|
Apr 24
|
BriaCell Announces Oral and Poster Presentations at ASCO 2024
|
|
Apr 10
|
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer
|
|
Apr 9
|
BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR
|
|
Mar 7
|
BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies
|
|
Mar 6
|
BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference
|
|
Feb 27
|
BriaCell Provides Update on Alleged Illegal Trading of Public Securities
|
|
Jan 4
|
BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer
|
|
Dec 28
|
BriaCell Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients
|
|
Dec 20
|
BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset
|
|
Dec 18
|
BCTX: Down in San Antone
|
|
Dec 6
|
BriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS
|
|
Dec 6
|
BriaCell 2023 SABCS Posters Confirm Activation of Cancer-Fighting Immune Cells and Identify Potential Predictors of Clinical Benefit
|
|
Dec 1
|
Here's Why We're Watching BriaCell Therapeutics' (TSE:BCT) Cash Burn Situation
|
|
Nov 30
|
BriaCell Records New Responder with Remarkable Improvement of “Eye-Bulging” Metastatic Tumor
|
|
Nov 8
|
BCTX: November 2023 SITC Poster
|
|
Nov 3
|
BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS™ IND
|